CONMED Corp (CNMD) stock forecast and price target
Price $50.59 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($50.59)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $4.57 | −0.4% | $1.4B |
| Next fiscal year ends December 31, 2027 | $4.75 | +3.9% | $1.4B |
| Next quarter ends December 31, 2026 | $1.26 | −11.6% | $367M |
| Quarter after ends March 31, 2027 | $0.98 | +10.1% | $329M |
Consensus of the analysts covering CONMED, updated daily. In the last 30 days 6 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 7.4% downside over 12 months. Our discounted cash flow model with moderate assumptions puts CONMED’s intrinsic value about 5% below today’s market value, and it scores 2.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the CONMED stock price target?
The average 12-month target from 6 analysts is $46.83, 7.4% below the current price of $50.59 Targets range from $43.00 to $50.00.
Is CONMED a buy according to analysts?
The consensus rating is “Hold” (6 hold, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is CONMED expected to earn?
Analysts expect EPS of $4.57 for the fiscal year ending December 31, 2026 and $4.75 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.